Abstract
Abstract The content for this activity is based on the CME Forum Focus on Uterine Fibroids: Evolving Options to Optimize Care that was presented at the 2017 ACOG Annual Clinical and Scientific Meeting in San Diego, California, on May 8, 2017. (Online access: http://courses.elseviercme.com/acog17/714e) Uterine fibroids, the most common benign pelvic tumors, affect nearly 70% of white women and more than 80% of African American women in the United States by the age of 50 years. They cause significant morbidity, as up to 50% of women with fibroids experience symptoms, including heavy menstrual bleeding, dysmenorrhea, and reproductive dysfunction. The current mainstay of management is surgical: uterine fibroids account for approximately one-third of all hysterectomies annually in the United States. Until recently, medical management options have been of limited value because of moderate efficacy and/or associated adverse effects. Novel therapies in late-stage development, including oral treatments, may offer better long-term medical management options. http://courses.elseviercme.com/alzheimer/593e
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call